Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Neoplasms 1NSCLC 1Lung Neoplasms 1Leukemia, Myeloid, Chronic-Phase 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 15Paclitaxel 15Carboplatin 13Specimen Handling 6Biopsy 6durvalumab 5Magnetic Resonance Spectroscopy 5dostarlimab 4Taxes 4Surveys and Questionnaires 4Observation 4Letrozole 4Everolimus 4Cisplatin 4olaparib 3lenvatinib 3ceralasertib 3Doxorubicin 3sacituzumab govitecan 2pertuzumab 2copanlisib 2cabozantinib 2atezolizumab 2abemaciclib 2Trastuzumab 2Robotic Surgical Procedures 2Pemetrexed 2Nivolumab 2Metformin 2Megestrol Acetate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Endometrial Neoplasms × Tyrosine Kinase Inhibitors × Clear all
NCT05824481 2026-03-10

Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer

Sun Yat-sen University

Phase 2 Active not recruiting
32 enrolled
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡